539 related articles for article (PubMed ID: 29974642)
1. Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification.
Krzanowski M; Krzanowska K; Dumnicka P; Gajda M; Woziwodzka K; Fedak D; Grodzicki T; Litwin JA; Sułowicz W
Ther Apher Dial; 2018 Oct; 22(5):519-529. PubMed ID: 29974642
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risk in chronic kidney disease patients: intima-media thickness predicts the incidence and severity of histologically assessed medial calcification in radial arteries.
Janda K; Krzanowski M; Gajda M; Dumnicka P; Fedak D; Lis GJ; Jaśkowski P; Pietrzycka A; Litwin JA; Sułowicz W
BMC Nephrol; 2015 Jun; 16():78. PubMed ID: 26037625
[TBL] [Abstract][Full Text] [Related]
3. Pentraxin 3 as a new indicator of cardiovascular‑related death in patients with advanced chronic kidney disease.
Krzanowski M; Krzanowska K; Gajda M; Dumnicka P; Dziewierz A; Woziwodzka K; Litwin JA; Sułowicz W
Pol Arch Intern Med; 2017 Feb; 127(3):170-177. PubMed ID: 28377558
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis.
Janda K; Krzanowski M; Chowaniec E; Kuśnierz-Cabala B; Dumnicka P; Kraśniak A; Podolec P; Sułowicz W
Pol Arch Med Wewn; 2013; 123(4):149-55. PubMed ID: 23535831
[TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethylarginine as a useful risk marker of radial artery calcification in patients with advanced kidney disease.
Krzanowski M; Krzanowska K; Gajda M; Dumnicka P; Kopeć G; Guzik B; Woziwodzka K; Dziewierz A; Litwin JA; Sułowicz W
Pol Arch Intern Med; 2018 Mar; 128(3):157-165. PubMed ID: 29600966
[TBL] [Abstract][Full Text] [Related]
6. FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients.
Turan MN; Kircelli F; Yaprak M; Sisman AR; Gungor O; Bayraktaroglu S; Ozkahya M; Asci G; Floege J; Ok E
Int Urol Nephrol; 2016 Apr; 48(4):609-17. PubMed ID: 26865177
[TBL] [Abstract][Full Text] [Related]
7. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease.
Bozic M; Méndez-Barbero N; Gutiérrez-Muñoz C; Betriu A; Egido J; Fernández E; Martín-Ventura JL; Valdivielso JM; Blanco-Colio LM;
Atherosclerosis; 2018 Mar; 270():13-20. PubMed ID: 29407881
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.
Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W
Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817
[TBL] [Abstract][Full Text] [Related]
9. Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients.
Kurnatowska I; Grzelak P; Kaczmarska M; Stefańczyk L; Nowicki M
Nephron Clin Pract; 2011; 117(4):c297-304. PubMed ID: 20861651
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3-5.
Marques GL; Hayashi S; Bjällmark A; Larsson M; Riella M; Olandoski M; Lindholm B; Nascimento MM
Sci Rep; 2021 Jan; 11(1):2473. PubMed ID: 33510348
[TBL] [Abstract][Full Text] [Related]
11. Circulating osteoprotegerin and asymptomatic carotid atherosclerosis in postmenopausal non diabetic women.
Albu A; Bondor CI; Crăciun AM; Fodor D
Adv Med Sci; 2014 Sep; 59(2):293-8. PubMed ID: 25240503
[TBL] [Abstract][Full Text] [Related]
12. Serum osteoprotegerin and carotid intima-media thickness in acute/chronic coronary artery diseases.
Ciccone MM; Scicchitano P; Gesualdo M; Zito A; Carbonara R; Locorotondo M; Mandurino C; Masi F; Boccalini F; Lepera ME
J Cardiovasc Med (Hagerstown); 2013 Jan; 14(1):43-8. PubMed ID: 22772598
[TBL] [Abstract][Full Text] [Related]
13. Impaired fasting glucose and diabetes as predictors for radial artery calcification in end stage renal disease patients.
Janda K; Krzanowski M; Gajda M; Dumnicka P; Fedak D; Lis GJ; Jaśkowski P; Litwin JA; Sułowicz W
Int J Endocrinol; 2013; 2013():969038. PubMed ID: 24454371
[TBL] [Abstract][Full Text] [Related]
14. Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic haemodialysis patients.
Peng Y; Liu H; Liu F; Ouyang L; Cheng M; Gao L; Pan F; Liu Y; Chen X; Li J
Nephrology (Carlton); 2008 Oct; 13(7):579-86. PubMed ID: 19161364
[TBL] [Abstract][Full Text] [Related]
15. Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function.
Collado S; Coll E; Nicolau C; Azqueta M; Pons M; Cruzado JM; de la Torre B; Deulofeu R; Mojal S; Pascual J; Cases A
BMC Nephrol; 2017 Sep; 18(1):290. PubMed ID: 28882110
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease.
Nascimento MM; Hayashi SY; Riella MC; Lindholm B
Braz J Med Biol Res; 2014 Nov; 47(11):995-1002. PubMed ID: 25296363
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.
Morena M; Jaussent I; Dupuy AM; Bargnoux AS; Kuster N; Chenine L; Leray-Moragues H; Klouche K; Vernhet H; Canaud B; Cristol JP
Nephrol Dial Transplant; 2015 Aug; 30(8):1345-56. PubMed ID: 25854266
[TBL] [Abstract][Full Text] [Related]
18. Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification.
Pérez de Ciriza C; Moreno M; Restituto P; Bastarrika G; Simón I; Colina I; Varo N
Clin Biochem; 2014 Dec; 47(18):272-8. PubMed ID: 25218813
[TBL] [Abstract][Full Text] [Related]
19. Tight relations between coronary calcification and atherosclerotic lesions in the carotid artery in chronic dialysis patients.
Kurnatowska I; Grzelak P; Stefańczyk L; Nowicki M
Nephrology (Carlton); 2010 Mar; 15(2):184-9. PubMed ID: 20470277
[TBL] [Abstract][Full Text] [Related]
20. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.
Fernández-Laso V; Sastre C; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM
Clin J Am Soc Nephrol; 2016 Mar; 11(3):413-22. PubMed ID: 26728587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
